This same study found that AML patients responding to standard chemotherapy had levels of Lin-CD127+CRTH2-CD117+NKp46+ cells comparable to normal donors while patients who failed to respond to therapy maintained reduced percentages, suggesting this population may have prognostic relevance in the setting of AML [32]. This evidence concerns the gene NCR1 and acute myeloid leukemia.